Want to see AU:EIQ full AI Analyst Report?
Top Page
EchoIQ Limited
(Sydney:EIQ)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$2.00
â–²(65.29% Upside)
Action:Reiterated
Date:07/03/26
Overall score is held down primarily by weak financial performance (shrinking revenue, negative gross profit, large operating losses, and ongoing cash burn). Technicals are a key positive (strong uptrend and positive MACD), but the very high RSI indicates momentum may be overextended. Valuation provides limited support given the company is loss-making and no dividend yield is available.
Positive Factors
Conservative balance sheet
A near-zero debt profile materially reduces solvency and interest-rate risk over the medium term. With little to no fixed financing costs the company has flexibility to prioritize operational adjustments or raise capital on its own timetable, which supports survival through extended recovery periods.
Negative Factors
Shrinking revenue trend
Sustained top-line contraction weakens the business’s ability to achieve scale, absorb fixed costs, or improve unit economics. Over several quarters this trend pressures margins, lengthens the path to break-even, and increases dependence on external funding or dilution to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A near-zero debt profile materially reduces solvency and interest-rate risk over the medium term. With little to no fixed financing costs the company has flexibility to prioritize operational adjustments or raise capital on its own timetable, which supports survival through extended recovery periods.
Read all positive factors
EchoIQ Limited (EIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.16B
Dividend YieldN/A
Average Volume (3M)2.50M
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue Growth-30.02%
EPS Growth-54.94%
CountryAU
Employees220
SectorHealthcare
Sector Strength45
IndustryOther Precious Metals
Share Statistics
EPS (TTM)-0.03
Shares Outstanding660,862,730
10 Day Avg. Volume1,343,747
30 Day Avg. Volume2,496,323
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.66
Price to Sales (P/S)1270.57
P/FCF Ratio-19.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.71Price Target Upside41.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$7.93M
EchoIQ Limited Business Overview & Revenue Model
Company Description
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, ...
How the Company Makes Money
null...
EchoIQ Limited Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.91K | 101.41K | 44.50K | 107.33K | 251.10K | 441.98K |
| Gross Profit | -9.09M | -3.14M | -2.88M | -7.01M | -3.19M | -1.75M |
| EBITDA | -15.58M | -12.74M | -4.81M | -7.66M | -5.85M | -3.14M |
| Net Income | -15.71M | -13.26M | -5.41M | -8.27M | -5.99M | -2.99M |
Balance Sheet | ||||||
| Total Assets | 17.99M | 23.37M | 8.26M | 10.38M | 10.23M | 10.93M |
| Cash, Cash Equivalents and Short-Term Investments | 11.21M | 6.62M | 2.12M | 3.28M | 2.41M | 3.81M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.83K |
| Total Liabilities | 718.61K | 615.41K | 1.49M | 3.00M | 2.21M | 1.10M |
| Stockholders Equity | 17.27M | 22.76M | 6.77M | 7.38M | 8.02M | 9.84M |
Cash Flow | ||||||
| Free Cash Flow | -8.34M | -6.54M | -3.92M | -5.28M | -2.95M | -2.43M |
| Operating Cash Flow | -8.28M | -6.51M | -3.92M | -4.94M | -2.58M | -1.43M |
| Investing Cash Flow | -2.06M | -11.55M | 0.00 | -59.81K | -367.33K | -1.00M |
| Financing Cash Flow | 16.21M | 22.56M | 2.77M | 5.88M | 1.55M | 2.77M |
EchoIQ Limited Technical Analysis
Positive
1.21
Price Trends
1.22
Positive
0.99
Positive
0.63
Positive
Market Momentum
0.12
Negative
78.56
Negative
71.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EIQ, the sentiment is Positive. The current price of 1.21 is below the 20-day moving average (MA) of 1.34, below the 50-day MA of 1.22, and above the 200-day MA of 0.63, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 78.56 is Negative, neither overbought nor oversold. The STOCH value of 71.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EIQ.
EchoIQ Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$96.37M | 17.80 | 11.24% | ― | 10.71% | ― | |
52 Neutral | AU$1.16B | -69.12 | -78.48% | ― | -30.02% | -54.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$36.22M | -3.09 | -62.57% | ― | 36.04% | -71.94% | |
40 Underperform | AU$51.29M | -19.82 | -16.92% | ― | 11.52% | 41.43% | |
40 Underperform | AU$6.28M | -0.56 | 783.67% | ― | -13.82% | -132.50% |
* Healthcare Sector Average
AU:EIQ
EchoIQ Limited
1.75
1.50
600.00%
AU:UBN
Urbanise.com
0.65
-0.22
-25.29%
AU:HPG
hipages Group Holdings Ltd.
0.71
-0.28
-28.06%
AU:AR9
archTIS Ltd.
0.08
-0.18
-70.24%
AU:PRO
Prophecy International Holdings Ltd
0.08
-0.34
-81.43%
EchoIQ Limited Corporate Events
Echo IQ secures exclusive access to up to 1 million cardiac imaging studies via Advara deal
Jul 1, 2026
Echo IQ has signed an exclusive data licensing agreement with Advara HeartCare, Australia’s largest private cardiovascular diagnostics provider, gaining access to between 500,000 and 1,000,000 de-identified echocardiography studies and linke...
EchoIQ plans sizeable equity placement on ASX
Jul 1, 2026
EchoIQ Limited has notified the ASX of a proposed placement of up to 75,862,069 ordinary fully paid shares. The new securities are expected to be issued on 7 July 2026, subject to the usual listing rule requirements and quotation processes.The cap...
Echo IQ raises A$110m to accelerate U.S. push and expand cardiovascular AI platform
Jul 1, 2026
Echo IQ has secured firm commitments for an institutional placement of approximately A$110 million at A$1.45 per share, issuing about 75.9 million new shares at an 8.8% discount and expanding its capital base by roughly 11.5 percent. The raise was...
EchoIQ Requests ASX Trading Halt Ahead of Material Capital Raising
Jun 28, 2026
EchoIQ Limited has requested a trading halt on its ordinary shares on the ASX as it prepares to announce a material capital raising, with the suspension to remain in place until either 1 July 2026 or the release of the funding announcement. The co...
EchoIQ Plans Issue of Convertible Notes and Options to Raise Capital
Jun 25, 2026
EchoIQ Limited has outlined plans for a new capital raising through a placement or similar structure, proposing to issue up to 20 million secured convertible notes and 15 million options. The new securities are targeted for issue on 31 August 2026...
Echo IQ secures strategic Pro Medicus deal to fund and fast-track US push
Jun 24, 2026
Echo IQ has entered a binding Heads of Agreement with global health imaging leader Pro Medicus for a proposed strategic investment of up to A$20 million and a US-focused commercial partnership. The deal framework includes an initial A$10 million i...
EchoIQ Tightens Governance With Updated Securities Trading Policy
Jun 19, 2026
EchoIQ Limited has updated its Securities Trading Policy following an annual review of its corporate governance framework, with the board adopting an amended version now available on the company’s website. The move underscores the cardiology...
EchoIQ Relocates Corporate Head Office to Central Sydney
Jun 9, 2026
EchoIQ Limited has announced a change to its principal place of business and corporate head office, which is now located at Level 11, 66 Clarence Street in Sydney, Australia, effective immediately. The company stated that all other contact details...
EchoIQ Issues 2.35 Million Unquoted Options Under Employee Incentive Scheme
May 26, 2026
EchoIQ Limited has notified the market of the issue of 2,350,000 unquoted options under its employee incentive scheme, recorded as security code EIQAAU. The options, which are not intended to be quoted on the ASX, form part of the company’s ...
Echo IQ secures $762k R&D tax incentive to advance AI cardiology tools
May 26, 2026
Echo IQ Limited has received $762,662 under the Australian Government’s Research and Development Tax Incentive Scheme for the financial year ended 30 June 2025. The refund recognises the company’s eligible RD expenditure on artificial ...
Echo IQ flags U.S. growth push with Mayo Clinic and Mount Sinai deals ahead of investor webinar
May 7, 2026
Echo IQ will host an investor webinar on 14 May 2026 to brief shareholders on strong U.S. commercial traction, including an expanded EchoSolv HF agreement with the Mayo Clinic that could open distribution across its platform network and more than ...
Echo IQ Accelerates U.S. Rollout as EchoSolv Usage Surges and Mayo, Mount Sinai Deals Advance
Apr 29, 2026
Echo IQ reported strong U.S. commercial momentum in the March quarter, highlighted by a distribution agreement with Mayo Clinic for EchoSolv HF once cleared, deployment of EchoSolv AS at New York’s Mount Sinai Health System, and a pipeline o...
Echo IQ deploys AI aortic stenosis tool at top-ranked Mount Sinai Health System
Apr 27, 2026
Echo IQ has deployed its EchoSolv AS decision support software for severe aortic stenosis into New York’s Mount Sinai Health System, which includes seven hospitals, more than 400 outpatient practices and a top-ranked cardiovascular program. ...
EchoIQ Director Increases Indirect Shareholding via Performance Rights Conversion
Apr 10, 2026
EchoIQ Limited has disclosed a change in director Steve Formica’s indirect holdings, following the vesting and exercise of a tranche of performance rights linked to the company’s share price. Through related party investment entities, ...
Echo IQ Issues New Shares on Exercise of Performance Rights
Apr 10, 2026
Echo IQ Limited has issued 1,625,000 fully paid ordinary shares following the exercise of vested performance rights, expanding its quoted share capital on the Australian Securities Exchange. The company advised that the shares were issued without ...
EchoIQ seeks quotation for 1.63 million new ASX shares
Apr 10, 2026
EchoIQ Limited has applied to the ASX for quotation of 1,625,000 additional ordinary fully paid shares, with an issue date of April 9, 2026. The new securities arise from the exercise or conversion of existing options or other convertible instrume...
Echo IQ issues 1 million new shares through option exercise
Apr 8, 2026
Echo IQ Limited has issued 1,000,000 fully paid ordinary shares following the exercise of unlisted options priced at $0.35 and expiring in June 2028, with the new shares forming part of its existing class quoted on the ASX. The company confirmed t...
EchoIQ seeks ASX quotation for 1 million new ordinary shares
Apr 8, 2026
EchoIQ Limited has applied for quotation on the ASX of 1,000,000 new ordinary fully paid shares, with an issue date of 8 April 2026. The application under Appendix 2A indicates these securities result from the exercise or conversion of existing in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.